Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
A293 | BMS patent anti-Integrin α5β1 Biosimilar(Anti-Integrin a5b1 (ITGA5 & ITGB1) Reference Antibody) Featured |
![]() |
|
A226 | Eblasakimab Biosimilar(Anti-IL-13Ra1 / CD213a1 Reference Antibod) Featured |
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells.
More description
|
![]() |
A1061 | Osemitamab Biosimilar(Anti-CLDN18.2 Reference Antibody) Featured |
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
More description
|
![]() |
A736 | Ivonescimab Biosimilar Featured |
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research.
More description
|
![]() |
A1060 | Muromonab Biosimilar(Anti-CD3 Reference Antibody) Featured |
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
More description
|
![]() |
A1059 | Atoltivimab Biosimilar(Anti-EBOV Reference Antibody) Featured |
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
More description
|
![]() |
A1058 | Navivumab Biosimilar(Anti-HA Reference Antibody) Featured |
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2.
More description
|
![]() |
A1057 | Anti-IAV Reference Antibody Biosimilar Featured |
![]() |
|
A1056 | Odesivimab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured |
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
More description
|
![]() |
A1055 | Cosfroviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured |
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
More description
|
![]() |
A1054 | Porgaviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured |
Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
More description
|
![]() |
A1053 | Larcaviximab Biosimilar(Anti-Zaire Ebola virus Reference Antibody) Featured |
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
More description
|
![]() |
A1052 | Romlusevimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
More description
|
![]() |
A1051 | Cilgavimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.
More description
|
![]() |
A1050 | Regdanvimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
More description
|
![]() |
A1049 | Tixagevimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
More description
|
![]() |
A1048 | Etesevimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody.
More description
|
![]() |
A1047 | Sotrovimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease.
More description
|
![]() |
A1046 | Amubarvimab Biosimilar(Anti-Spike RBD Reference Antibody) Featured |
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
More description
|
![]() |
A1045 | Semzuvolimab Biosimilar(Anti-CD4 Reference Antibody) Featured |
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection.
More description
|
![]() |
A1044 | Temtokibart Biosimilar(Anti-IL22RA1 Reference Antibody) Featured |
Temtokibart is a humanized IgG1λ2 antibody targeting IL22RA1. Expressed by cells lacking the glutamine synthetase gene.
More description
|
![]() |
A1043 | Maftivimab Biosimilar(Anti-Zaire ebolavirus Reference Antibody) Featured |
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection.
More description
|
![]() |
A1042 | Ansuvimab Biosimilar(Anti-Zaire ebolavirus Reference Antibody) Featured |
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells.
More description
|
![]() |
A1041 | Iluzanebart Biosimilar(Anti-TREM2 Reference Antibody) Featured |
Iluzanebart is a human IgG1κ antibody targeting TREM2, a triggering receptor expressed on myeloid cells.
More description
|
![]() |
A1040 | Burfiralimab Biosimilar(Anti-Vimentin Reference Antibody) Featured |
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
More description
|
![]() |
A1039 | Dalnicastobart Biosimilar(Anti-TNFRSF5 / CD40 Reference Antibody) Featured |
Dalnicastobart (LVGN-7409) is a human IgG1κ antibody targeting CD40/TNFRSF5.
More description
|
![]() |
A1038 | Stapokibart Biosimilar(Anti-IL-4Ra / CD124 Reference Antibody) Featured |
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats.
More description
|
![]() |
A1037 | Raludotatug Biosimilar(Anti-CDH6 / K-Cadherin Reference Antibody) Featured |
Raludotatug is a humanized immunoglobulin G1-kappa, anti-CDH6 monoclonal antibody. Raludotatug is an antineoplastic.
More description
|
![]() |
A1036 | Izeltabart Biosimilar(Anti-ADAM9 Reference Antibody) Featured |
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models.
More description
|
![]() |
A1035 | Keliximab Biosimilar(Anti-CD4 Reference Antibody) Featured |
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.
More description
|
![]() |